4Q23 results included charges related to the Daiichi Sankyo collaboration .

Meanwhile Steglujan (ertugliflozin+sitagliptin), a fixed dose combination combining the SGLT2 with Merck’s Januvia, is approved in type 2 disease when patients who need both drugs. Ertugliflozin ...

Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing once-daily administration. In drug-naïve subjects with type 2 ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Global Diabetes Drug Market growth is driven by the rising incidence of diabetes and increasing adoption of innovative treatment solutions.Austin, United States, Feb. 10, 2025 (GLOBE NEWSWIRE) -- ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Several DPP-4 inhibitors are in clinical development; one (sitagliptin) has been approved by the FDA, and another (vildagliptin) has been applied for approval. Both of these compounds are ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...